(Reuters) - Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.
The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021.
Both trials are testing Xtandi in men with hormone-sensitive prostate cancer.
Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.
Prostate cancer is the second most common cancer in men worldwide and over 164,000 men in the United States are estimated to be newly diagnosed with the disease this year, according to the American Cancer Society.
Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.